BeiGene, Ltd. (BGNE)
- Previous Close
144.12 - Open
148.40 - Bid 148.45 x 100
- Ask 149.11 x 100
- Day's Range
146.16 - 152.83 - 52 Week Range
126.97 - 266.67 - Volume
406,915 - Avg. Volume
240,748 - Market Cap (intraday)
15.782B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-8.71 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
272.37
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
www.beigene.comRecent News: BGNE
Performance Overview: BGNE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BGNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BGNE
Valuation Measures
Market Cap
16.33B
Enterprise Value
14.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.31
Price/Book (mrq)
4.39
Enterprise Value/Revenue
5.73
Enterprise Value/EBITDA
-12.58
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.86%
Return on Assets (ttm)
-12.40%
Return on Equity (ttm)
-22.26%
Revenue (ttm)
2.46B
Net Income Avi to Common (ttm)
-881.71M
Diluted EPS (ttm)
-8.71
Balance Sheet and Cash Flow
Total Cash (mrq)
3.17B
Total Debt/Equity (mrq)
26.30%
Levered Free Cash Flow (ttm)
-1.27B